Rhodococcus equi infection after alemtuzumab therapy for T-cell prolymphocytic leukemia

Rhodococcus equi, mainly known from veterinary medicine as a pathogen in domestic animals, can also cause infections in immunocompromised humans, especially in those with defects in cellular immunity. Alemtuzumab, an anti-CD52 monoclonal antibody, causes lymphocytopenia by eliminating CD52-positive...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Emerging infectious diseases 2007-12, Vol.13 (12), p.1942-1943
Hauptverfasser:	Meeuse, Jan J, Sprenger, Herman G, van Assen, Sander, Leduc, Dominique, Daenen, Simon M G J, Arends, Jan P, van der Werf, Tjip S
Format:	Artikel
Sprache:	eng
Schlagworte:	Actinomycetales Infections - etiology Actinomycetales Infections - microbiology Aged Alemtuzumab Anti-Bacterial Agents - therapeutic use Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antibodies, Neoplasm - adverse effects Antibodies, Neoplasm - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cancer Care and treatment Development and progression Dispatch Health aspects Humans Immunocompromised Host Infection Leukemia Leukemia, Prolymphocytic, T-Cell - drug therapy Lung Abscess - drug therapy Lung Abscess - microbiology Male Rhodococcus equi T cells T-PLL the Netherlands
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Rhodococcus equi, mainly known from veterinary medicine as a pathogen in domestic animals, can also cause infections in immunocompromised humans, especially in those with defects in cellular immunity. Alemtuzumab, an anti-CD52 monoclonal antibody, causes lymphocytopenia by eliminating CD52-positive cells. We report a patient in whom Rhodococcus equi infection developed after alemtuzumab therapy.
ISSN:	1080-6040 1080-6059
DOI:	10.3201/eid1312.061559